Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.58 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.58 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.58 |
| ▸ | CETP | P11597 | 1/20 | 0.52 |
| ▸ | GJB2 | P29033 | 1/20 | 0.50 |
| ▸ | IGF2R | P11717 | 4/20 | 0.49 |
| ▸ | GBA1 | P04062 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10718936 | 1.00 | MAPK1 (0.67) | MAPK1LGALS8LGALS3LGALS4CETP | |
| SCHEMBL605059 | 1.00 | MAPK1 (0.67) | MAPK1LGALS8LGALS3LGALS4CETP | |
| SCHEMBL604620 | 1.00 | MAPK1 (0.67) | MAPK1LGALS8LGALS3LGALS4CETP | |
| SCHEMBL7556272 | 1.00 | MAPK1 (0.67) | MAPK1LGALS8LGALS3LGALS4CETP | |
| SCHEMBL606489 | 1.00 | MAPK1 (0.67) | MAPK1LGALS8LGALS3LGALS4CETP | |
| SCHEMBL9184499 | 1.00 | MAPK1 (0.67) | MAPK1LGALS8LGALS3LGALS4CETP | |
| SCHEMBL608556 | 1.00 | MAPK1 (0.67) | MAPK1LGALS8LGALS3LGALS4CETP | |
| SCHEMBL15353544 | 1.00 | MAPK1 (0.67) | MAPK1LGALS8LGALS3LGALS4CETP | |
| SCHEMBL606440 | 1.00 | MAPK1 (0.67) | MAPK1LGALS8LGALS3LGALS4CETP | |
| SCHEMBL607064 | 1.00 | MAPK1 (0.67) | MAPK1LGALS8LGALS3LGALS4CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030119762-A1 | 5'-substituted-ribofuranosyl benzimidazoles as antiviral agents | TOWNSEND LEROY B (US) | 2003-06-26 | — | — | US | disclosed |
| EP-0845001-B1 | 5'-SUBSTITUTED-RIBOFURANOSYL BENZIMIDAZOLES AS ANTIVIRAL AGENTS | UNIV MICHIGAN (US) | 2002-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119762-A1 | 5'-substituted-ribofuranosyl benzimidazoles as antiviral agents | ZC3HAV1, ZC3HAV1L, IFNAR1 | MAPK1 3396/4885LGALS8 2837/4885LGALS3 1980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.